Key result
Higher pulse wave velocity measured by phase-contrast cardiac magnetic resonance imaging predicted an increased risk of major adverse cardiovascular events in patients with COPD (HR 4.75).
Why the study?
Does pulmonary artery stiffness measured by CMR predict major adverse cardiovascular events in patients with COPD and suspected secondary pulmonary hypertension?
Cohort (n=60)
Single-blind
No
Does pulmonary artery stiffness measured by CMR predict major adverse cardiovascular events in patients with COPD and suspected secondary pulmonary hypertension?
Hazard Ratio: 4.75 (95% CI 1–22.59)
p-value: p=0.03
CMR-derived pulse wave velocity is a valuable non-invasive marker for identifying pulmonary hypertension and predicting adverse cardiovascular events in patients with COPD.
No takes yet. Share an insight, caveat, or question.
CMR PWV may aid MACE risk stratification in COPD with suspected PH; hypothesis-generating and requires validation before practice change.
Agoşton-Coldea et al. (2018) conducted a cohort in Chronic Obstructive Pulmonary Disease (COPD) with suspected secondary Pulmonary Hypertension (PH) (n=60). Pulse wave velocity (PWV) by phase-contrast cardiac magnetic resonance imaging vs. Lower pulse wave velocity was evaluated on Major adverse cardiovascular events (MACEs) including cardiac death, ventricular tachyarrhythmia, and heart failure (HR 4.75, 95% CI 1.00 to 22.59, p=0.03). Higher pulse wave velocity measured by phase-contrast cardiac magnetic resonance imaging predicted an increased risk of major adverse cardiovascular events in patients with COPD (HR 4.75).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: